GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » Selling, General, & Admin. Expense

Lexaria Bioscience (Lexaria Bioscience) Selling, General, & Admin. Expense : $2.67 Mil (TTM As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Lexaria Bioscience's selling, general, & admin. expense for the three months ended in Feb. 2024 was $0.57 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Feb. 2024 was $2.67 Mil.


Lexaria Bioscience Selling, General, & Admin. Expense Historical Data

The historical data trend for Lexaria Bioscience's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience Selling, General, & Admin. Expense Chart

Lexaria Bioscience Annual Data
Trend Oct13 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.64 3.98 4.97 4.96 3.06

Lexaria Bioscience Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.82 0.57 0.71 0.57

Competitive Comparison of Lexaria Bioscience's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Lexaria Bioscience's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Selling, General, & Admin. Expense falls into.



Lexaria Bioscience Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexaria Bioscience  (NAS:LEXX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Lexaria Bioscience Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry
Traded in Other Exchanges
N/A
Address
740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Executives
Catherine C. Turkel director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Gregory Downey officer: Chief Financial Officer 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka director, 10 percent owner, officer: CEO 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Vanessa Carle officer: Secretary 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Reese Albert L Jr director
Brian W. Quigley director 100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie director 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger officer: CFO 8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty director, 10 percent owner 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar director, officer: CFO 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter director 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford director 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke officer: Sr. VP, Business Development 38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini director, 10 percent owner 11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan director, officer: Vice President - Corp Develop SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6